DDInter350 DDInter574
A nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant and nonmalignant diseases. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting forms of MS lead to neurological symptoms that resolve and recur periodically. More than 80% of patients suffering from this disease have relapsing-remitting MS. Diroximel fumarate is a new drug from the fumarate class formulated to treat various relapsing forms of MS. This drug is bioequivalent to [Dimethyl fumarate][A187544,L9626](initially manufactured in 2013), but is less likely to cause gastrointestinal side effects, owing to its unique chemical structure. Diroximel fumarate was formulated by Alkermes in collaboration with Biogen, and was approved by the FDA in October 2019 and by the EMA in November 2021.
Chlorambucil {u} (Compound) resembles {v} (Compound) Melphalan
Melphalan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Chlorambucil {u} (Compound) treats {v} (Disease) ovarian cancer
ovarian cancer {u} (Disease) is treated by {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Chlorambucil {u} (Compound) resembles {v} (Compound) Melphalan
Melphalan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydroxyurea
Hydroxyurea {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Chlorambucil {u} (Compound) treats {v} (Disease) breast cancer
breast cancer {u} (Disease) is palliated by {v} (Compound) Dexamethasone
Dexamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Chlorambucil {u} (Compound) resembles {v} (Compound) Melphalan
Melphalan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ocrelizumab
Ocrelizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Chlorambucil {u} (Compound) binds {v} (Gene) SLCO1A2
SLCO1A2 {u} (Gene) is bound by {v} (Compound) Dexamethasone
Dexamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Chlorambucil {u} (Compound) upregulates {v} (Gene) DDB2
DDB2 {u} (Gene) is upregulated by {v} (Compound) Melphalan
Melphalan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Chlorambucil {u} (Compound) upregulates {v} (Gene) LRPAP1
LRPAP1 {u} (Gene) is downregulated by {v} (Compound) Azacitidine
Azacitidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Chlorambucil {u} (Compound) upregulates {v} (Gene) PHLDA3
PHLDA3 {u} (Gene) is upregulated by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Diroximel fumarate
Chlorambucil {u} (Compound) resembles {v} (Compound) Melphalan
Melphalan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Chlorambucil (Compound) resembles Melphalan (Compound) and Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Chlorambucil (Compound) treats ovarian cancer (Disease) and ovarian cancer (Disease) is treated by Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Chlorambucil (Compound) resembles Melphalan (Compound) and Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyurea and Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Chlorambucil (Compound) treats breast cancer (Disease) and breast cancer (Disease) is palliated by Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Chlorambucil (Compound) resembles Melphalan (Compound) and Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Chlorambucil (Compound) binds SLCO1A2 (Gene) and SLCO1A2 (Gene) is bound by Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Chlorambucil (Compound) upregulates DDB2 (Gene) and DDB2 (Gene) is upregulated by Melphalan (Compound) and Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Chlorambucil (Compound) upregulates LRPAP1 (Gene) and LRPAP1 (Gene) is downregulated by Azacitidine (Compound) and Azacitidine may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Chlorambucil (Compound) upregulates PHLDA3 (Gene) and PHLDA3 (Gene) is upregulated by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Diroximel fumarate
Chlorambucil (Compound) resembles Melphalan (Compound) and Melphalan may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate